Customize your JAMA Network experience by selecting one or more topics from the list below.
On September 19, 2007, MedImmune Vaccines (Gaithersburg, Maryland)
received approval from the Food and Drug Administration (FDA) to expand the use of FluMist®, a live, attenuated influenza vaccine (LAIV),
to children aged 2-4 years (i.e., 24-49 months). FluMist is an intranasally administered influenza vaccine that was first licensed by the FDA in 2003 for healthy, nonpregnant persons aged 5-49 years.1 Expanding the age indications to include healthy children aged 2-4 years provides another influenza vaccination option for young children. In granting the new approval, FDA emphasized that FluMist is not approved for vaccination of children aged <2 years or adults aged >49 years,
and that FluMist safety has not been established in persons with underlying medical conditions predisposing them to influenza-related complications.2 In addition, FluMist should not be administered to persons with asthma or children aged <5 years with recurrent wheezing.1,2
Notice to Readers: Expansion of Use of Live Attenuated Influenza Vaccine (FluMist®) to Children Aged 2-4 Years and Other FluMist Changes for the 2007-08 Influenza Season. JAMA. 2008;299(2):166–167. doi:10.1001/jama.299.2.166
Create a personal account or sign in to: